How Should Medical Aesthetic Providers Evaluate Suspicious Skin Lesions And Pigmentation Prior To Administering Laser, Light, Or Microneedling Therapies? Essential Safety Screening

Do not treat an uncertain lesion as a cosmetic problem. Before laser, light-based, or microneedling therapy, providers should perform a structured visual and clinical screening for features that may indicate melanoma, basal cell carcinoma, squamous cell carcinoma, or a precancerous lesion. Any lesion that is suspicious, changing, symptomatic, or diagnostically uncertain should be excluded from treatment and referred promptly to a physician or dermatologist for evaluation and, when indicated, biopsy.

Aesthetic devices and microneedling should be used only on lesions that have been appropriately identified as benign. When malignancy cannot be confidently excluded, stop treatment and refer for medical assessment before proceeding.

Why Lesion Screening Must Come First

Cosmetic pigmentation can resemble disease

Solar lentigines, seborrheic keratoses, melasma, and benign nevi may appear similar to atypical or malignant pigmented lesions. Visual similarity alone is not enough to justify treating a lesion cosmetically.

Treatment can obscure a developing problem

Laser or light treatment may alter a lesion’s color, surface, or borders, potentially making later assessment more difficult. Microneedling should likewise not be performed over an unexplained or suspicious lesion.

The central safety issue is not whether the device can remove pigment. It is whether the provider has established that the target is appropriate for elective treatment.

Malignancy must be excluded medically

Melanoma and lentigo maligna are contraindications to aesthetic laser treatment. If there is meaningful uncertainty about a lesion’s malignant potential, the appropriate next step is medical evaluation and, when indicated, diagnostic biopsy—not a test spot or partial cosmetic treatment.

How to Screen a Lesion Before Treatment

Apply the ABCDE framework

Providers can use the ABCDE criteria as a screening aid:

Asymmetry: One half does not resemble the other.
Border: The edge is irregular, jagged, notched, or poorly defined.
Color: The lesion contains multiple colors or has developed new color variation.
Diameter: A lesion larger than approximately 6 millimeters, or one that is enlarging, deserves attention.
Evolution: The lesion is changing in size, shape, color, texture, or symptoms.

Elevation or a rough, raised surface can also be concerning, but evolution is the more useful “E” criterion. A lesion does not need to satisfy every ABCDE feature to warrant referral.

Look for additional warning signs

Do not treat a lesion that:

Bleeds without a clear explanation
Crusts, ulcerates, or repeatedly fails to heal
Grows rapidly
Becomes persistently itchy, painful, or tender
Develops a new nodule or rough surface
Differs noticeably from the patient’s other lesions
Shows a new or changing dark streak, spot, or patch

A concerning lesion may be subtle, particularly in heavily sun-damaged skin or in patients with darker skin tones.

Compare the lesion with surrounding skin

The provider should assess the lesion in context rather than viewing it as an isolated cosmetic target. A new “ugly duckling” lesion that looks different from the patient’s other nevi should not be treated without appropriate medical assessment.

What to Do When a Lesion Is Suspicious

Stop treatment on the lesion

Do not apply laser, IPL, or other light-based energy to a suspicious pigmented lesion. Do not needle over it, and do not use a test spot as a substitute for diagnosis.

The lesion should be documented according to the provider’s practice and regulatory requirements, while avoiding language that implies a definitive cancer diagnosis outside the provider’s scope.

Refer to the appropriate clinician

Refer the patient to a physician or dermatologist for examination. The clinician may determine that monitoring is appropriate or may recommend biopsy and histopathologic assessment.

Aesthetic treatment should not resume on that lesion until its status and treatment suitability have been medically clarified.

Explain the decision transparently

Patients may expect immediate treatment because they view the lesion as unwanted pigmentation. Explain that the concern is safety: altering an undiagnosed lesion could delay recognition of a serious condition.

A clear referral is not a treatment failure. It demonstrates appropriate clinical judgment and protects the patient from preventable harm.

Evaluate the Patient, Not Only the Lesion

Review relevant contraindications

The consultation should include factors that affect treatment safety, including:

Active infection or inflammation
History of poor wound healing or severe scarring
Previous abnormal or changing lesions
Recent tanning or significant sun exposure
Medications or conditions affecting healing or pigmentation
Prior adverse reactions to laser, light, or needling procedures

Providers should not proceed when the overall risk is unacceptable merely because the patient wants treatment or the procedure is commercially attractive.

Identify the patient’s primary concern

If the patient presents for pigmentation, address that concern first while explaining how other issues—such as wrinkles or texture—might be managed separately. This keeps the treatment plan clinically focused instead of allowing unrelated findings to distract from lesion screening.

Obtain appropriate baseline information

Record the lesion’s location, appearance, symptoms, and relevant history when permitted by the practice’s procedures. Standardized photographs can support continuity, but they do not replace examination or biopsy when malignancy is suspected.

Distinguish Screening From Diagnosis

Skin analyzers can support assessment

Magnified examination, cross-polarized imaging, multispectral imaging, and other diagnostic tools may help visualize pigment distribution, vascular features, borders, and superficial structural patterns. They can improve documentation and help identify lesions that require referral.

Devices cannot rule out cancer

No aesthetic skin analyzer can reliably replace a qualified medical examination or histopathology. Claims that imaging can determine lesion depth or benignity with certainty should be treated cautiously.

Terms such as Breslow thickness and Clark level are clinical pathology and staging concepts, not substitutes for biopsy. A provider should never use an analyzer’s output as permission to laser an uncertain lesion.

Classify confirmed benign targets

Once a lesion has been appropriately assessed as benign, the clinician should consider whether its pigment is primarily epidermal, dermal, or mixed. This classification can influence the choice of wavelength, pulse duration, spot size, energy, and treatment strategy.

The patient’s skin type and tendency toward post-inflammatory hyperpigmentation or scarring must also be incorporated into the plan.

Use a Safe Treatment Process for Appropriate Targets

Perform a complete consultation

A sound consultation should include:

Consult: Review the concern, history, medications, skin type, and contraindications.
Listen: Clarify the patient’s actual treatment goal.
Inform: Explain expected sensations, risks, alternatives, and likely treatment course.
Execute: Treat only an appropriately selected and clinically cleared target.
Nurture: Provide aftercare and monitor healing.
Thank: Confirm follow-up and invite the patient to report unexpected changes.

This process keeps informed consent connected to the actual clinical decision rather than treating consent as a substitute for evaluation.

Consider a test spot for suitable benign treatment

For an appropriate benign target, a test spot may help assess the skin’s thermal response and reduce the risk of unexpected pigmentary change or scarring. This is particularly important when treating darker skin types, including Fitzpatrick types III–VI.

A test spot is a parameter-safety measure. It is not a diagnostic test for malignancy and must never be performed on a suspicious lesion.

Plan follow-up

Give the patient clear instructions about expected redness, swelling, crusting, pigmentary changes, and warning signs. Confirm follow-up when clinically appropriate, especially after higher-powered laser procedures or treatments involving significant epidermal disruption.

Understanding the Trade-offs

Cosmetic delay is preferable to diagnostic delay

The main downside of referral is that treatment may be postponed. That inconvenience is minor compared with the risk of masking a melanoma or delaying treatment for another skin cancer.

Advanced imaging improves documentation, not certainty

Skin imaging may help reveal patterns that are difficult to see with unaided inspection. However, relying on a device as a definitive cancer-screening system can create false reassurance and inappropriate treatment.

More aggressive treatment increases risk

High-powered lasers and deeper microneedling can produce stronger clinical effects, but they also increase the consequences of incorrect target selection. Greater energy or penetration does not compensate for an incomplete diagnosis.

Pigment recurrence is not always treatment failure

Even a confirmed benign pigmentary condition may recur because of ongoing ultraviolet exposure, hormonal influences, inflammation, or mixed epidermal and dermal involvement. Providers should avoid escalating treatment simply because pigment returns without reassessing the diagnosis and treatment plan.

Making the Right Choice for Your Goal

Use the following approach to keep patient safety ahead of procedural momentum:

If your primary focus is identifying possible skin cancer: Apply a structured lesion screen, stop treatment on any suspicious or changing lesion, and refer promptly for physician or dermatology evaluation.
If your primary focus is treating confirmed benign pigmentation: Document the diagnosis or medical clearance, classify the target appropriately, account for skin type and pigmentary risk, and use conservative parameters with appropriate follow-up.
If your primary focus is reducing treatment complications: Review contraindications, avoid active infection and high-risk patients, consider a test spot only on an appropriate benign target, and provide clear aftercare.
If your primary focus is managing patient expectations: Explain that referral or postponement is a safety decision, not a refusal of care, and discuss suitable alternatives only after the lesion has been medically assessed.

When a lesion is uncertain, the safest and most professional treatment is referral before any aesthetic procedure.

Summary Table:

Screening Criterion	What to Look For	Action
A - Asymmetry	One half doesn't match the other	Do not treat; refer to dermatologist
B - Border	Irregular, jagged, notched, or poorly defined edges	Do not treat; refer to dermatologist
C - Color	Multiple colors or new color variation	Do not treat; refer to dermatologist
D - Diameter	Larger than 6 mm or enlarging	Do not treat; refer to dermatologist
E - Evolution	Changing in size, shape, color, texture, or symptoms	Do not treat; refer to dermatologist
Additional Warning Signs	Bleeds, crusts, ulcerates, rapidly grows, itchy, painful, tender, nodule, rough surface, 'ugly duckling'	Do not treat; refer to dermatologist

Ensure the highest safety standards for your aesthetic practice. At BELIS, we provide professional-grade medical aesthetic equipment exclusively for clinics and premium salons. Our advanced laser systems (Diode, Alexandrite, CO2, Erbium, Nd:YAG, Pico), IPL, and PDT devices, along with HIFU, microneedle RF, body sculpting, and skin analysis tools, are designed to meet your clinical needs. Partner with us to access certified, reliable technology and expert support. For distributors, we offer OEM/ODM services, competitive profit margins, and full certifications. Contact our team today (#ContactForm) to discuss how BELIS can elevate your practice and ensure patient safety with every treatment.